common reactions include transient pain, erythema, or pruritus at the administration site, along with mild diarrhea, headache, or nausea in a minority of recipients
Development was discontinued because the Phase IIb trial of 536 subjects over 24 weeks failed to meet its primary efficacy endpoint
AOD-9604 Safety Profile and Potential Side Effects Safety data from over 900 clinical trial participants provides comprehensive information about AOD-9604s tolerability, side effect profile, and important contraindications
a larger Intramuscular (in the muscle) 25 gauge 1 inch or 1.5 inch needle for maximum intramuscular benefit and a smaller Deep Subcutaneous (under skin) 28-30 gauge inch needle or 25g 5/8 inch
This deficiency is common, affecting approximately 6% of people under the age of 60 and 20% of people over the age of 60